新发透析患者对乙型肝炎主动疫苗接种的应答与死亡率的关系
这项回顾性队列研究纳入2001至2008年间在奥地利两家透析中心开始透析的426例新发透析患者,分析乙型肝炎疫苗接种应答与全因、心血管及感染相关死亡率的关系。中位随访51.2个月期间228例(53.5%)死亡,达到血清转换和血清保护与全因死亡率显著降低独立相关。
要点
- 426例新发透析患者中,207例(48.6%)无应答,219例(51.4%)血清转换,118例(27.7%)血清保护。
- 血清保护者全因死亡风险HR 0.69(95%CI 0.49-0.97,p=0.03),血清转换者HR 0.72(95%CI 0.55-0.95,p=0.02)。
- 血清保护与血清转换者全因及心血管死亡率均显著较低(全因p<0.001;心血管p=0.006和p=0.01)。
核心结论
- 新发透析患者接种乙型肝炎疫苗后达到血清转换和血清保护与全因死亡率显著降低相关。
- 该简单易得工具可在独立于年龄、性别、糖尿病及营养不良和炎症标志物等已知关键参数的情况下评估患者生存。
研究设计与样本
- 回顾性队列研究,纳入2001至2008年间在奥地利两家透析中心开始透析的新发透析患者426例。
- 疫苗接种应答定义:抗-HBs抗体滴度缺失或<10IU/L为无应答,血清转换为滴度≥10IU/L,血清保护为滴度≥100IU/L。
- 采用Kaplan-Meier生存曲线和多变量校正Cox比例风险模型分析疫苗接种应答与全因、心血管及感染相关死亡率的关系。
主要发现
- 207例(48.6%)无应答,219例(51.4%)血清转换,118例(27.7%)血清保护。
- 中位随访51.2个月期间228例(53.5%)死亡。
- 血清保护者和血清转换者全因死亡率均显著较低(两者p<0.001),心血管死亡率亦显著较低(血清保护p=0.006,血清转换p=0.01)。
- 血清保护和血清转换与全因死亡率显著风险降低独立相关(血清保护:HR 0.69,95%CI 0.49-0.97,p=0.03;血清转换:HR 0.72,95%CI 0.55-0.95,p=0.02)。
临床怎么用
- 所有晚期慢性肾脏病或接受肾脏替代治疗的患者应接种乙型肝炎主动疫苗。
- 接种后达到血清转换和血清保护可提示新发透析患者全因死亡率降低。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
All patients with advanced chronic kidney disease or on renal replacement therapy should receive active hepatitis B vaccination. The aim of this retrospective cohort study was to investigate the association between the immune response to hepatitis B vaccination and all-cause, cardiovascular or infection-related mortality in incident dialysis patients starting dialysis between 2001 and 2008 (n=426) in two Austrian dialysis centers. Vaccination response was defined as follows: absent anti-HBs antibody titer or a titer <10IU/L was classified as non-response, seroconversion (SC) was defined as a titer ⩾10IU/L, and seroprotection (SP) as a titer ⩾100IU/L. Kaplan-Meier survival curves and multivariable adjusted Cox Proportional Hazards Models were used to determine the association between vaccination response and all-cause, cardiovascular and infection-related mortality. Of all patients 207 (48.6%) were non-responders, SC was observed in 219 (51.4%), SP in 118 (27.7%) patients. During a median follow-up of 51.2 months 228 (53.5%) patients died. Patients with SP and SC showed a significantly lower all-cause (p<0.001 for both) and cardiovascular mortality (p=0.006 for SP, p=0.01 for SC). SP and SC were independently associated with a significant risk reduction for all-cause mortality (SP: HR 0.69, 95% CI 0.49-0.97, p=0.03; SC: HR 0.72, 95% CI 0.55-0.95, p=0.02). In conclusion, achieving seroconversion and seroprotection after active hepatitis B vaccination is associated with significantly reduced all-cause mortality in incident dialysis patients. This simple and readily available tool allows estimation of patient survival independently of other well-known key parameters such as age, gender, the presence of diabetes and markers of malnutrition and inflammation.
引用
- Zitt E, Hafner-Giessauf H, Wimmer B, et al. Response to active hepatitis B vaccination and mortality in incident dialysis patients. Vaccine. 2016. PMID: 28049587. doi:10.1016/j.vaccine.2016.12.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。